Relevium Provides Regulatory Update Pursuant to Temporary Relief Granted by Regulators Due to COVID-19
July 06 2020 - 6:27PM
Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to
provide a regulatory update pursuant to the temporary relief
granted by regulators due to COVID-19.
On June 2, 2020 The Company issued a regulatory
update and the delayed filing of the third quarter of fiscal year
ending June 30, 2020. As required by the provisions of the
temporary relief, we are pleased to announce that during the 30-day
period the company has issued four news releases to update the
market as follows:
- On June 11, 2020 the Company issued a news release pleased to
announce the successful delivery of CleanCare™ Hand Sanitizers to
retail customers in the in the US, including the orders announced
in a news release on April 15th of this year.
- On June 19, 2020 the Company announced it had expanded and
continues to expand its CleanCare™ product line as it prepares to
address increased government and institutional demand for
disinfection supplies in preparation for a potential second wave of
COVID-19.
- On June 23, 2020 the Company announced the addition of
award-winning marketing executive James Mansour to its advisory
board. ON the same date the company issued a statement of
clarification about its Bioganix CleanCare brand, separating itself
from another product using “CleanCare” in its branding.
DELAYED FILING OF INTERIM DISCLOSURE
DOCUMENTS PURSUANT TO TEMPORARY RELIEF GRANTED BY REGULATORS DUE TO
COVID-19
On May 27, 2020, Relevium announced that it
would be delaying the filing and delivery of certain of its
continuous disclosure documents, in accordance with Decision No
2020-PDG-0023 of the Autorité des marchés financiers (Québec) (the
“Exemption”), which was adopted for the purpose of providing
certain filing and other relief to issuers in light of the
challenges posed by the COVID-19 pandemic.
The Company is relying on the Exemption for the
delay in the filing of its quarterly financial statements and
related management discussion and analysis
(“MD&A”) for the period ended March 31, 2020
required pursuant to National Instrument 51-102 Continuous
Disclosure Obligations and the filing of the related certifications
(collectively, the "Required Filings") and
compliance with the delivery requirements of applicable securities
laws relating to the Required Filings. The Company intends to file
the Required Filings by July 14, 2020.
The Company does not foresee any delays in regard to any other
ongoing disclosure obligations.
Blackout in Effect for Management and
Other Insiders
In accordance with the Corporation's Securities
Trading Policy, the officers and directors of the Corporation and
certain other persons will remain subject to a trading black-out
pursuant to which such persons are prohibited from trading in any
securities of the Corporation until such time the Required Filings
are filed on SEDAR and a corresponding news release is issued by
the Corporation.
The Company endeavours to keep shareholders
informed about its progress through online shareholder updates and
news releases.
About Relevium Technologies
Relevium is a publicly traded Company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition, and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe.
Relevium’s premium brands are sold at some of
the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical Company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
Cautionary Note Regarding
Forward-Looking Statements
This release includes certain statements and
information that may constitute forward-looking information within
the meaning of applicable Canadian and United States securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions, or expectations of future
performance, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", or "would" occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com Website:
www.releviumtechnologies.com Like us on FacebookFollow us on
Twitter Follow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024